These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9561200)

  • 1. X-ray crystallographic studies of the structure-function relationships of HIV-1 protease.
    Hong L; Zhang C; Hartsuck JA; Foundling S; Tang J
    Adv Exp Med Biol; 1998; 436():59-63. PubMed ID: 9561200
    [No Abstract]   [Full Text] [Related]  

  • 2. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
    J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.
    Ganguly AK; Alluri SS; Caroccia D; Biswas D; Wang CH; Kang E; Zhang Y; McPhail AT; Carroll SS; Burlein C; Munshi V; Orth P; Strickland C
    J Med Chem; 2011 Oct; 54(20):7176-83. PubMed ID: 21916489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptability and flexibility of HIV-1 protease.
    Kumar M; Hosur MV
    Eur J Biochem; 2003 Mar; 270(6):1231-9. PubMed ID: 12631281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the 3D structure of HIV-1 protease.
    Kent S; Marshall GR; Wlodawer A
    Science; 2000 Jun; 288(5471):1590. PubMed ID: 10858137
    [No Abstract]   [Full Text] [Related]  

  • 12. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies.
    Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE
    Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742
    [No Abstract]   [Full Text] [Related]  

  • 13. Activated dynamics of flap opening in HIV-1 protease.
    Collins JR; Burt SK; Erickson JW
    Adv Exp Med Biol; 1995; 362():455-60. PubMed ID: 8540357
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor.
    Hill R
    Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407
    [No Abstract]   [Full Text] [Related]  

  • 15. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
    J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
    Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
    J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease.
    Altman MD; Nalivaika EA; Prabu-Jeyabalan M; Schiffer CA; Tidor B
    Proteins; 2008 Feb; 70(3):678-94. PubMed ID: 17729291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining mutations in HIV-1 protease to understand mechanisms of resistance.
    Mahalingam B; Boross P; Wang YF; Louis JM; Fischer CC; Tozser J; Harrison RW; Weber IT
    Proteins; 2002 Jul; 48(1):107-16. PubMed ID: 12012342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative molecular field analysis (CoMFA), topomer CoMFA, and hologram QSAR studies on a series of novel HIV-1 protease inhibitors.
    Heidari A; Fatemi MH
    Chem Biol Drug Des; 2017 Jun; 89(6):918-931. PubMed ID: 27933723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.